Cumberland Pharmaceuticals (CPIX, Financial) experienced a significant stock surge of 5.92%. The stock is now valued at $1.25 per share with a trading volume of 39,480 shares and a turnover rate of 0.28%. The stock's price volatility has reached 7.63%.
Despite its rising stock price, the company's recent financial report indicates a revenue of $9.85 million, with a net loss of $1.09 million and an earnings per share of -$0.08. The gross profit stands at $7.00 million, and the price-to-earnings ratio is currently -1.68. There are no recent buy, hold, or sell ratings from agencies for CPIX.
In the broader pharmaceutical industry, there's been a general decline of 2.66%. Amongst its peers, Scilex Holding Company, Sunshine Biopharma Inc, and Supernus Pharmaceuticals have recorded considerable gains. Canopy Growth Corporation, Sunshine Biopharma Inc., and Biofrontera Inc. have been notably active, with turnover rates of 12.37%, 10.50%, and 9.48%, respectively. Stocks showing high volatility include Gelteq Limited and Scilex Holding Company, with price fluctuations of 20.88% and 20.69% respectively.
Cumberland Pharmaceuticals specializes in the acquisition, development, and commercialization of branded prescription drugs. The company targets hospital acute care, gastroenterology, rheumatology, and oncology markets. It promotes FDA-approved branded products like Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol, and Vibativ across the U.S. and through international partnerships.
